AbbVie Snatches Up Antibody from Harbour BioMed to Fight COVID-19 and Related Mutations
The Pharma Data
DECEMBER 14, 2020
Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S.
Let's personalize your content